Shareholders to Vote on Massive Dilution from $45M Financing and Expanded Equity Plan

summarizeSummary

This definitive proxy statement outlines critical proposals for PAVmed Inc.'s upcoming special shareholder meeting. The most impactful proposals involve approving the issuance of common stock from a recent $45 million financing (Series D Preferred Stock, Warrants, and 2026 Note) and a substantial increase in the company's equity incentive plan. The conversion of the Series D Preferred Stock and 2026 Note alone could lead to over 600% dilution for existing common stockholders, with the Series D conversion price ($6.50) significantly below the current market price ($9.99). This financing, previously announced on February 4, 2026, is crucial for the company's operational runway, but comes at an extreme cost to current shareholder value. Additionally, the proposal to add 1.5 million shares to the equity plan represents further significant dilution, approximately 15.9% of the fully diluted share count. While the charter amendment to permit director removal without cause is a positive governance change, its impact is overshadowed by the severe dilution. Investors should be aware of the substantial dilution risk if these proposals are approved.

check_boxKey Events

• Special Shareholder Meeting Scheduled

  A special meeting of stockholders is scheduled for March 27, 2026, to vote on critical proposals, finalizing the preliminary proxy filed on February 13, 2026.

• Massive Dilution from Financing Approval

  Shareholders will vote on approving the issuance of common stock upon conversion of 60,000 Series D Preferred Stock (from a $30M private placement) and a $15M Senior Secured Convertible Note. This could result in over 600% dilution for existing common stockholders, with the Series D conversion price of $6.50 per share being below the current market price.

• Significant Increase in Equity Plan

  A proposal seeks to increase the total number of shares available under the 2014 Long-Term Incentive Equity Plan by an additional 1,500,000 shares, representing approximately 15.9% of the fully diluted common stock after the other proposed conversions.

• Governance Change Proposed

  Stockholders will vote on amending the company's certificate of incorporation to permit the removal of any director, with or without cause, by the affirmative vote of a majority of the outstanding voting power.

auto_awesomeAnalysis

This definitive proxy statement outlines critical proposals for PAVmed Inc.'s upcoming special shareholder meeting. The most impactful proposals involve approving the issuance of common stock from a recent $45 million financing (Series D Preferred Stock, Warrants, and 2026 Note) and a substantial increase in the company's equity incentive plan. The conversion of the Series D Preferred Stock and 2026 Note alone could lead to over 600% dilution for existing common stockholders, with the Series D conversion price ($6.50) significantly below the current market price ($9.99). This financing, previously announced on February 4, 2026, is crucial for the company's operational runway, but comes at an extreme cost to current shareholder value. Additionally, the proposal to add 1.5 million shares to the equity plan represents further significant dilution, approximately 15.9% of the fully diluted share count. While the charter amendment to permit director removal without cause is a positive governance change, its impact is overshadowed by the severe dilution. Investors should be aware of the substantial dilution risk if these proposals are approved.